Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.39 |
| ▸ | AKT1 | P31749 | 4/20 | 0.39 |
| ▸ | MTOR | P42345 | 3/20 | 0.39 |
| ▸ | RAF1 | P04049 | 5/20 | 0.38 |
| ▸ | PIK3R1 | P27986 | 4/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.38 |
| ▸ | SCD | O00767 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29434090 | 1.00 | ROCK2 (0.40) | ROCK2PIK3CDPIK3CAAKT1MTOR | |
| SCHEMBL24766050 | 0.80 | ATR (0.39) | PIK3CDPIK3CAAKT1MTORPIK3R1 | |
| SCHEMBL29434132 | 0.78 | PIM1 (0.49) | RAF1BRAF | |
| SCHEMBL24766055 | 0.78 | PIM1 (0.49) | RAF1BRAF | |
| SCHEMBL20029213 | 0.74 | USP2 (0.48) | ROCK2PIK3CDPIK3CAAKT1MTOR | |
| SCHEMBL24766072 | 0.74 | PIM1 (0.52) | PIK3CA | |
| SCHEMBL3763461 | 0.72 | NOS1 (0.57) | ROCK2PIK3CDPIK3CAMTORPIK3R1 | |
| SCHEMBL24851269 | 0.71 | USP2 (0.54) | PIK3CDPIK3CAMTOR | |
| SCHEMBL24312197 | 0.69 | AKT1 (0.43) | AKT1RAF1BRAF | |
| SCHEMBL24766067 | 0.69 | LRRK2 (0.48) | PIK3CDPIK3CAAKT1MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11407737-B2 | Inhibitors of RAF kinases | KINNATE BIOPHARMA INC. (US) | 2022-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11407737-B2 | Inhibitors of RAF kinases | BRAF, RAF1, ARAF | ROCK2 236/4885PIK3CD 154/4885PIK3CA 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.